(BLCO) Bausch + Lomb - Overview

Sector: HealthcareIndustry: Medical Instruments & Supplies | Exchange NYSE (USA) | Currency USD | Market Cap: 5.642m | Total Return 2.5% in 12m

Stock: Contact Lenses, Eye Drops, Pharmaceuticals, Surgical Devices

Total Rating 30

Risk 54

Buy Signal -0.83

Medical Instruments & Supplies -3.1
Health Care Supplies -10.4

Market Cap: 5,642m
Avg Trading Vol: 6.80M USD

ATR: 3.54%
Peers RS (IBD): 81.3

Risk 5d forecast
Volatility	40.8%
Relative Tail Risk	-10.7%

Reward TTM
Sharpe Ratio	0.18
Alpha	-15.95

Character TTM
Beta	1.144
Beta Downside	1.418

Drawdowns 3y
Max DD	48.07%
CAGR/Max DD	-0.09

EPS (Earnings per Share)

EPS CAGR: 22.39%
EPS Trend: -28.4%

Last SUE: -0.17
Qual. Beats: 0

Revenue

Rev. CAGR: 12.98%
Rev. Trend: 94.5%

Last SUE: 0.05
Qual. Beats: 0

Description: BLCO Bausch + Lomb March 05, 2026

Bausch + Lomb Corporation (BLCO) is an eye health company operating globally, with significant presence in North America, Europe, and Asia. The company generates revenue through three primary segments: Vision Care, Pharmaceuticals, and Surgical.

The Vision Care segment focuses on contact lenses, including daily disposables and therapeutic lenses, alongside a range of over-the-counter eye care products. This segment caters to a broad consumer market for corrective and general eye health needs.

The Pharmaceuticals segment develops and markets proprietary and generic drugs for various eye conditions, such as glaucoma, inflammation, and retinal diseases. Pharmaceutical companies typically face regulatory hurdles and patent expirations.

The Surgical segment provides medical devices and technologies for eye surgeries, including cataract treatment and retinal procedures. Medical device companies often rely on innovation and clinical efficacy for market penetration.

BLCO distributes its products through direct sales forces and independent distributors. Further research on ValueRay can provide detailed financial metrics and competitive analysis.

Headlines to watch out for

Global demand for contact lenses drives Vision Care segment revenue
Pharmaceutical segment growth depends on new drug approvals and patent expirations
Surgical equipment sales influenced by cataract and retinal procedure volumes
Foreign currency fluctuations impact international revenue and profitability
Regulatory approvals for new products are critical for market access

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income: -360.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA -0.01 > 1.0
NWC/Revenue: 20.72% < 20% (prev 21.92%; Δ -1.19% < -1%)
CFO/TA 0.02 > 3% & CFO 283.4m > Net Income -360.0m
Net Debt (4.99b) to EBITDA (572.0m): 8.72 < 3
Current Ratio: 1.55 > 1.5 & < 3
Outstanding Shares: last quarter (353.8m) vs 12m ago 0.57% < -2%
Gross Margin: 58.71% > 18% (prev 0.61%; Δ 5.81k% > 0.5%)
Asset Turnover: 37.11% > 50% (prev 35.57%; Δ 1.54% > 0%)
Interest Coverage Ratio: 0.35 > 6 (EBITDA TTM 572.0m / Interest Expense TTM 431.0m)

Altman Z'' 0.06

A: 0.08 (Total Current Assets 2.98b - Total Current Liabilities 1.92b) / Total Assets 14.02b
B: -0.07 (Retained Earnings -931.0m / Total Assets 14.02b)
C: 0.01 (EBIT TTM 151.0m / Avg Total Assets 13.75b)
D: -0.28 (Book Value of Equity -2.12b / Total Liabilities 7.50b)
Altman-Z'' Score: 0.06 = B

Beneish M -2.91

DSRI: 1.12 (Receivables 1.22b/1.03b, Revenue 5.10b/4.79b)
GMI: 1.04 (GM 58.71% / 60.93%)
AQI: 0.97 (AQ_t 0.66 / AQ_t-1 0.68)
SGI: 1.06 (Revenue 5.10b / 4.79b)
TATA: -0.05 (NI -360.0m - CFO 283.4m) / TA 14.02b)
Beneish M-Score: -2.91 (Cap -4..+1) = A

What is the price of BLCO shares?

As of March 28, 2026, the stock is trading at USD 15.37 with a total of 316,498 shares traded.
Over the past week, the price has changed by -2.23%, over one month by -16.01%, over three months by -10.38% and over the past year by +2.47%.

Is BLCO a buy, sell or hold?

Bausch + Lomb has received a consensus analysts rating of 3.53. Therefor, it is recommend to hold BLCO.

StrongBuy: 3
Buy: 3
Hold: 8
Sell: 1
StrongSell: 0

What are the forecasts/targets for the BLCO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	18.5	20.1%
Analysts Target Price	18.5	20.1%

BLCO Fundamental Data Overview March 28, 2026

P/E Forward = 14.7493
P/S = 1.1061
P/B = 0.8638
P/EG = 0.6992
Revenue TTM = 5.10b USD
EBIT TTM = 151.0m USD
EBITDA TTM = 572.0m USD
Long Term Debt = 5.04b USD (from longTermDebt, last quarter)
Short Term Debt = 77.0m USD (from shortTermDebt, last quarter)
Debt = 5.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.99b USD (from netDebt column, last quarter)
Enterprise Value = 10.63b USD (5.64b + Debt 5.37b - CCE 383.0m)
Interest Coverage Ratio = 0.35 (Ebit TTM 151.0m / Interest Expense TTM 431.0m)
EV/FCF = -169.6x (Enterprise Value 10.63b / FCF TTM -62.7m)
FCF Yield = -0.59% (FCF TTM -62.7m / Enterprise Value 10.63b)
FCF Margin = -1.23% (FCF TTM -62.7m / Revenue TTM 5.10b)
Net Margin = -7.06% (Net Income TTM -360.0m / Revenue TTM 5.10b)
Gross Margin = 58.71% ((Revenue TTM 5.10b - Cost of Revenue TTM 2.11b) / Revenue TTM)
Gross Margin QoQ = 58.08% (prev 60.19%)
Tobins Q-Ratio = 0.76 (Enterprise Value 10.63b / Total Assets 14.02b)
Interest Expense / Debt = 2.01% (Interest Expense 108.0m / Debt 5.37b)
Taxrate = 21.0% (US default 21%)
NOPAT = 119.3m (EBIT 151.0m * (1 - 21.00%))
Current Ratio = 1.55 (Total Current Assets 2.98b / Total Current Liabilities 1.92b)
Debt / Equity = 0.83 (Debt 5.37b / totalStockholderEquity, last quarter 6.45b)
Debt / EBITDA = 8.72 (Net Debt 4.99b / EBITDA 572.0m)
Debt / FCF = -79.57 (negative FCF - burning cash) (Net Debt 4.99b / FCF TTM -62.7m)
Total Stockholder Equity = 6.42b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.62% (Net Income -360.0m / Total Assets 14.02b)
RoE = -5.61% (Net Income TTM -360.0m / Total Stockholder Equity 6.42b)
RoCE = 1.32% (EBIT 151.0m / Capital Employed (Equity 6.42b + L.T.Debt 5.04b))
RoIC = 1.05% (NOPAT 119.3m / Invested Capital 11.37b)
WACC = 5.90% (E(5.64b)/V(11.01b) * Re(10.01%) + D(5.37b)/V(11.01b) * Rd(2.01%) * (1-Tc(0.21)))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.43%
[DCF] Fair Price = unknown (Cash Flow -62.7m)
EPS Correlation: -28.39 | EPS CAGR: 22.39% | SUE: -0.17 | # QB: 0
Revenue Correlation: 94.46 | Revenue CAGR: 12.98% | SUE: 0.05 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.16 | Chg7d=-0.002 | Chg30d=+0.002 | Revisions Net=-2 | Analysts=12
EPS current Year (2026-12-31): EPS=0.78 | Chg7d=+0.005 | Chg30d=-0.005 | Revisions Net=-4 | Growth EPS=+53.3% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=1.07 | Chg7d=+0.011 | Chg30d=-0.011 | Revisions Net=+0 | Growth EPS=+37.0% | Growth Revenue=+5.7%
[Analyst] Revisions Ratio: -0.20 (4 Up / 6 Down within 30d for Next Quarter)

Additional Sources for BLCO Stock

Fund Manager Positions: Dataroma | Stockcircle